DAIICHI SANKYO CO., LTD
|
|
|
- Claire Snow
- 5 years ago
- Views:
Transcription
1 Briefing for 3Q FY2013 (April 1 December 31, 2013) DAIICHI SANKYO CO., LTD Manabu Sakai Senior Executive Officer, Head of Corporate Management Division Friday, January 31, :00 ~ 16:00
2 Overview 3Q YTD Consolidated Income Statement Ranbaxy Group Note : Figures of Ranbaxy are pre-adjusted before consolidation FY2012 3Q FY2013 3Q YoY FY2012 (Jan-Sep) FY2013 (Jan-Sep) YoY Net Sales Cost of Sales SG&A Expenses R&D Expenses Other Expenses Operating Income % +7.0% % -84.4% Ordinary Income % Net Income % Currency Rate USD/JPY EUR/JPY INR/JPY Average Currency rate
3 3Q YTD Net Sales Positive Factors(+) Negative Factors(-) FY2012 Q Japan (incl. OTC) Japan Nexium +27.5, Memary +6.5, Ranmark +2.8, Vaccines +2.1 Mevalotin -2.8 Global Business Ranbaxy * Forex Impact (USD,EUR,INR) Others Global business Daiichi Sankyo Inc. (DSI) -0.4 Luitpold Pharmaceuticals, Inc. (LPI) -8.0 Daiichi Sankyo Europe GmbH (DSE) +3.3 Asia, South and Central America (ASCA) +14.2* *including currency impact Ranbaxy (RLL) FY2012 3Q: Contribution of Atorvastatin etc. Currency Impact USD: EUR: INR: FY2013Q *Currency Rate USD/JPY EUR/JPY INR/JPY FY2012 3Q FY2013 3Q
4 3Q YTD Operating Income Positive Factors(+) Negative Factors(-) FY2012Q Daiich Sankyo Group Gross Profit Ranbaxy Group Gross Profit R&D Expenses -5.1 R&D expenses: Currency Impact Other Expenses SG&A exc. R&D expenses: Currency Impact FY2013Q
5 3Q YTD Ordinary Income / Net Income Ordinary Income 95.7 Positive Factors(+) Negative Factors(-) Non-operating Expenses: Ranbaxy: Higher loss on INR depreciation 88.5 Net Income Extraordinary Gains: Realized gain on sales of certain fixed assets and investment securities Extraordinary Losses: Provisions for restructuring in Europe Minority Interests: Minority s share of financial loss in RLL etc. 45
6 Major Products in Japan Sales results and Outlook FY2012 3Q FY2013 3Q Outlook FY2013 Progress Olmetec anti-hypertension % Rezaltas anti-hypertension % Loxonin Nexium analgesic and antiinflammatory % anti-ulcer (Proton Pump Inhibitor) % Cravit antibacterial % Memary treatment for Alzheimer % Artist anti-hypertension % Mevalotin anti-hyperlipidemia % Omnipaque contrast medium % Urief treatment for dysuria % Ranmark treatment for bone metastasis % 76 5
7 Major R&D Pipeline Therapeutic area Phase 1 Phase 2 Phase 3 Application Cardiovascular- Metabolics DS-7309 (Anti-diabetes / Glucokinase activator) DS-8500 (Anti-diabetes / GPR119 agonist) DS-1442 (Dyslipidemia / CETP inhibitor) CS-3150 (JP) (Anti-hypertensive/DM nephropathy / MR antagonist) CS-747 (JP) (prasugrel / ischemic stroke / anti-platelet agent) CS-747 (US) (prasugrel / Sickle Cell Disease / antiplatelet agent) CS-747 (JP) (prasugrel / PCI / anti-platelet agent) DU-176b (Global) (edoxaban / AF / oral factor Xa inhibitor) DU-176b (Global) (edoxaban / VTE / oral factor Xa inhibitor) DS-1040 (Acute ischemic stroke / TAFIa inhibitor) Oncology Others U (US/JP) (Anti-HB-EGF antibody) DS-2248 (US) (HSP90 inhibitor) DS-7423 (US/JP) (PI3K/mTOR inhibitor) DS-3078 (US/EU) (mtor inhibitor) DS-3032 (US) (MDM2 inhibitor) PLX7486(US) (Fms/Trk inhibitor) DS-8895( 日 ) (Anti-EPHA2 antibody) DS-8587 (Anti-bacterial / Topoisomerase inhibitor) CS-4771 (Anti-sepsis / TLR4 inhibitor) PLX5622 (Rheumatoid arthritis / FMS kinase inhibitor) CS-0777 (Immunomodulator / S1P receptor modulator) DS-1093 (Anemia of chronic kidney disease/hif-ph inhibitor) U (US/EU) (patritumab / anti-her3 antibody) PLX4032 (US/EU) (vemurafenib / BRAF inhibitor) PLX3397 (US) (Fms/Kit/Flt3-ITD inhibitor) DS-5565 (Global) (Chronic pain / α2δ ligand) SUN13837 (US/EU) (Spinal cord injury / Modulator of bfgf signaling system) ASB17061 (US) (Atopic Dermatitis / chymase inhibitor) CS-8958 (US/EU) (laninamivir / anti-influenza / Outlicensing with Biota) Change of stage from announcement in Oct 2013 ARQ 197 (US/EU) (tivantinib / HCC / Met inhibitor) AMG 162 (JP) (denosumab / breast cancer adjuvant / anti-rankl antibody) DE-766 (JP) (nimotuzumab / NSCLC / anti-egfr antibody) DE-766 (JP) (nimotuzumab / Gastric cancer / anti-egfr antibody) DR-3355 (JP) (levofloxacin / anti-infection / New quinolone) AMG 162 (JP) (denosumab / rheumatoid arthritis / anti-rankl anti-body) DS-7113 (hydromorphone / Narcotic analgesic / opioid mu-receptor regulator) AMG 162 (JP) (denosumab / Giant Cell tumor / anti-rankl antibody) 6 7
8 Consolidated Forecasts for the FY2013 Differences Between Japanese GAAP and IFRS (Rough Estimate) Japanese GAAP IFRS (estimate) Difference Net Sales 1, , Operating Income Income before income taxes Net Income Financial items under non-operating income/expenses and extraordinary income/losses are recorded as finance income/costs in IFRS and non-financial items are included in operating income. 2. Net income under IFRS is expressed as profit attributable to owners of the parent company in order to adjust it to a basis for comparison with Japanese GAAP. 87
9 Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.
DAIICHI SANKYO CO., LTD
Briefing for 2Q FY2013 (April 1 September 30, 2013) DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO November 1, 2013 Overview 2Q YTD Consolidated Income Statement Ranbaxy Group Note : Figures of
Reference Data (Consolidated Financial Results for Q3 FY2011)
TSE:4568 Reference Data (Consolidated Financial Results for Q3 FY2011) January 31, 2012 Daiichi Sankyo Co., Ltd. http://www.daiichisankyo.com MEMO (This page is intentionally left blank) Contents 1. Consolidated
Top Management Presentation Financial Results of FY2014
Top Management Presentation Financial Results of FY2014 DAIICHI SANKYO CO., LTD Joji Nakayama President and CEO May 15, 2015 Today s topics FY2014 Results FY2015 Forecast Mid-term management policy 1 FY2014
(April 1, September 30, 2008) October 31, 2008
(April 1, 2008 - September 30, 2008) October 31, 2008 Net Sales Cost of Sales SG&A R&D Total Expense Operating Income Ordinary Income Net Income Results for 2Q FY2008 (vs 2Q FY2007) FY2007 1st Half Results
Annual Report Daiichi Sankyo Co., Ltd.
Annual Report 212 Daiichi Sankyo Co., Ltd. Contents 1 Consolidated Financial Highlights 2 Message from the President 14 Company Information / Stock Information 15 Other Detailed Information Consolidated
Operations and Financial Position
Operations and Financial Position n Adoption of International Financial Reporting Standards (IFRS) Daiichi Sankyo and its consolidated subsidiaries ( the Group ) have adopted IFRS starting in the fiscal
Reference Data (Consolidated Financial Results for 1QFY2007)
Stock code number 4568 Reference Data (Consolidated Financial Results for ) [1]Summary of Financial Statement P1 [2]Currency Rate P1 [3]Consolidated sales of Global Product P2 [4]Overseas Sales P2 [5]Consolidated
DAIICHI SANKYO CO., LTD.
DAIICHI SANKYO CO., LTD. Contents 02 Interview with the President Daiichi Sankyo s Management and Priority Initiatives in Fiscal Year 2011 12 Feature 1 New Products Multiple Groundbreaking Product Launches
1. Consolidated Financial Results for Year Ended March 31, 2018 (1) Consolidated Financial Results
April 27, 2018 Consolidated Financial Results for Year Ended March 31, 2018 (Fiscal 2017) Listed company name: Daiichi Sankyo Company, Limited Listed exchange: First Section of the Tokyo Stock
Consolidated Financial Results for Fiscal 2015 (Year Ended March 31, 2016) <under IFRS>
Consolidated Financial Results for Fiscal 2015 (Year Ended March 31, 2016) May 12, 2016 Listed company name: Daiichi Sankyo Company, Limited Listed exchange: First Section of the Tokyo Stock
Daiichi Sankyo Company, Limited
CONVOCATION NOTICE OF THE 7 TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Period Ended March 31, 2012 Daiichi Sankyo Company, Limited *Note: This translation does not include pictures, charts
DAIICHI SANKYO CO., LTD. Annual Report 2009
DAIICHI SANKYO CO., LTD. Annual Report 2009 PROFILE Daiichi Sankyo Co., Ltd., was established in 2005, after the merger of two leading centuryold Japanese pharmaceutical companies. With more than 100 years
Strategic Roadmap Update and FY2015 Q1 Consolidated Financial Results Important notice Forward-Looking Statements Medical Information
Strategic Roadmap Update and FY2015 Q1 Consolidated Financial Results Christophe Weber, President & CEO Rudolf van Houten, Acting CFO & Group Financial Controller July 30, 2015 Important notice Forward-Looking
Daiichi Sankyo Company, Limited
CONVOCATION NOTICE OF THE 6 TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Period Ended March 31, 2011 Daiichi Sankyo Company, Limited - 1 - To Shareholders, (Securities Identification Code
Consolidated Financial Results FY2015 Q2
Consolidated Financial Results FY2015 Q2 October 30, 2015 Rudolf van Houten Acting CFO & Group Financial Controller Important Notice Forward-Looking Statements This presentation contains forward-looking
Financial Results for the Fiscal Year ended March 31, 2017 (IFRS, Consolidated)
Financial Results for the Fiscal Year ended March 31, 2017 (IFRS, Consolidated) Company name: Mitsubishi Tanabe Pharma Corporation Stock exchange listings: Tokyo Securities code number: 4508 URL: http://www.mt-pharma.co.jp/
FY 2013 Third Quarter Results. February 4, 2014 Santen Pharmaceutical Co., Ltd
FY 2013 Third Quarter Results February 4, 2014 Santen Pharmaceutical Co., Ltd 0 Financial Results for the FY2013 Third Quarter; Financial Forecast for the FY2013; Kazuo Koshiji Corporate Officer, Head
FY 2011 Third Quarter Results. February 7, 2012 Santen Pharmaceutical Co., Ltd
FY 2011 Third Quarter Results February 7, 2012 Santen Pharmaceutical Co., Ltd 1 Consolidated Results FY2011 Third Quarter Satoshi Harada Corporate Officer Head of Administration Division 2 Medium-term
Forward-Looking Statements. Consolidated Financial Results for the 3rd Quarter of Fiscal Year François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer February 5, 2015 Forward-Looking Statements This presentation contains forward-looking
Apr-Jun Apr-Jun. (billion yen) (billion yen) (billion yen) % (billion yen)
First Quarter of Fiscal 2012 Consolidated Financial Results Hiroshi Takahara Senior Vice President Corporate Finance & Controlling Department July 30, 2012 Consolidated Financial Results for the First
3rd Quarter of FY2015 Business Results
3rd Quarter of FY2015 Business Results (April December, 2015) February 3, 2016 Eizo Tabaru Board Director, Managing Executive officer General Manager of Finance & Accounting Dept. Overview of Q3 FY2015
FY 2013 First Quarter Results. August 6, 2013 Santen Pharmaceutical Co., Ltd
FY 2013 First Quarter Results August 6, 2013 Santen Pharmaceutical Co., Ltd 0 Consolidated Results FY2013 First Quarter Kazuo Koshiji Corporate Officer, Head of Finance & Administration Division 1 Med-term
Ranbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec 14 Sales Rs.81,778 Mn
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
(Figures are rounded down to the nearest million yen) 1. Consolidated Performance for the nine months ended December 31, 2013
[ Disclaimer: The following is meant to be an accurate translation from the original Financial Report of Santen Pharmaceutical Co., Ltd., written in Japanese, and is prepared for the information disclosure
Kyowa Hakko Kirin Co., Ltd.
Kyowa Hakko Kirin Co., Ltd. Consolidated Financial Summary Fiscal 2016 Interim (January 1, 2016 June 30, 2016) This document is an English translation of parts of the Japanese-language original. All financial
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
October 27, 2009 Ligand to Acquire Metabasis for Cash and Contingent Value Rights Ligand to Gain Fully Funded Partnership with Roche for Hepatitis and Promising Development-Stage Programs SAN DIEGO-- Ligand
Consolidated Financial Results for the Fiscal Year Ending March 31, 2013
Consolidated Financial Results for the Fiscal Year Ending March 31, 2013 1. Outline of Consolidated Financial Results 2. Highlights of Business Performance 3. Consolidated Financial Results 4. Main Product
(Figures are rounded down to the nearest million yen) 1. Consolidated Performance for the three months ended June 30, 2013
[ Disclaimer: The following is meant to be an accurate translation from the original Financial Report of Santen Pharmaceutical Co., Ltd., written in ese, and is prepared for the information disclosure
To Shareholders. Interim Report for the First Six Months of Fiscal Year 2016
To Our Shareholders I thank you sincerely for your ongoing support. Here, we provide an overview of the Company s operating performance during the first six months of fiscal year 216. To Shareholders Interim
First Quarter (April 1 June 30, 2014) Flash Report (unaudited) Three months ended June 30, 2014 ONO PHARMACEUTICAL CO., LTD. August 4, 2014 Ono Pharma
ONO PHARMACEUTICAL CO., LTD. August 4, Ono Pharmaceutical Co., Ltd. has announced its consolidated financial results for three months ended June 30,. The consolidated financial statements have been prepared
Investor Meeting on FY2015 Third Quarter Results and Revised FY2015 Forecasts Kazuo Koshiji
Investor Meeting on FY2015 Third Quarter Results and Revised FY2015 Forecasts Kazuo Koshiji Senior Corporate Officer Chief Financial Officer Head of Finance Division February 2, 2016 Santen s Corporate
Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2018
Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2018 1. Outline of Consolidated Financial Results P.1 2. Highlights of Business Performance P.2 3. Consolidated Financial
Investor Meeting on FY 2015 First Quarter Results Kazuo Koshiji
Investor Meeting on FY 2015 First Quarter Results Kazuo Koshiji Senior Corporate Officer Chief Financial Officer (CFO) Head of Finance Division August 4, 2015 Santen s Corporate Values 天機に参与する Tenki ni
Summary of 3rd Quarter Financial Results for year ended March 31, (Unaudited)
Summary of 3rd Quarter Financial Results for year ended March 31, 2010 (Unaudited) Company name: Stock exchange listings (Section): Securities code number: URL: Representative: For further information,
Third quarter dividends per share (yen) Second quarter dividends per share (yen)
[ Disclaimer : The following is meant to be an accurate translation from the original Financial Report of Santen Pharmaceutical Co., Ltd., written in Japanese, and is prepared for the information disclosure
Investor Meeting on Q2 FY2016 Results
Investor Meeting on Q2 FY2016 Results Akira Kurokawa President & CEO November 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. Santen s Corporate Values By focusing on ophthalmology,
Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer
Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer Kazuaki Kitabatake February 8, 2018 Maintained Good Momentum despite
Investor Meeting on FY2015 Results and FY2016 Forecast
Investor Meeting on FY2015 Results and FY2016 Forecast Akira Kurokawa President & CEO May 12, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. Santen s Corporate Values By focusing
Consolidated Financial Results for the 1st Quarter of Fiscal Year 2014
Consolidated Financial Results for the 1st Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer August 1, 2014 Notes on Disclosure Shift to IFRS and Core earnings From Q1 2014 Takeda
Reports Third-Quarter Diluted EPS of $1.01 on a GAAP Basis; Adjusted Diluted EPS of $1.41, Reflecting Growth of 16.5 Percent
PRESS RELEASE AbbVie Reports Third-Quarter 2017 Financial Results Reports Third-Quarter Diluted EPS of $1.01 on a GAAP Basis; Adjusted Diluted EPS of $1.41, Reflecting Growth of 16.5 Percent Delivers Third-Quarter
Financial Results for the Fiscal Year ended March 31, 2018 (IFRS, Consolidated)
Financial Results for the Fiscal Year ended March 31, 2018 (IFRS, Consolidated) Company name: Mitsubishi Tanabe Pharma Corporation Stock exchange listings: Tokyo Securities code number: 4508 URL: https://www.mt-pharma.co.jp/
Consolidated Financial Results for the Interim Period ended September 30, Consolidated Financial Forecasts for the Year ending March 2005
Consolidated Financial Results for the Interim Period ended September 30, 2004 Consolidated Financial Forecasts for the Year ending March 2005 Ichiro Otokozawa Corporate Officer Head of Corporate Development
FY 2008 First Quarter Results. August 4, 2008 Santen Pharmaceutical Co., Ltd
FY 2008 First Quarter Results August 4, 2008 Santen Pharmaceutical Co., Ltd 1 FY 2008 First Quarter Consolidated Financial Results Chief Financial Officer Yoshihiro Noutsuka Forward-looking statements:
Santen Investor Meeting FY2015 First Half Results Akira Kurokawa
Santen Investor Meeting FY2015 First Half Results Akira Kurokawa President & CEO November 5, 2015 Santen s Corporate Values 天機に参与する Tenki ni sanyo suru By focusing our efforts on ophthalmology and related
Dr Reddy s Laboratories Ltd. Q4 FY07 and FY07 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Q4 and Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 05 Branded
Presentation of Fiscal 2003 Results. Akira Ohira, Executive Vice President Taisho Pharmaceutical May 19, 2004
Presentation of Fiscal 2003 Results Akira Ohira, Executive Vice President Taisho Pharmaceutical May 19, 2004 Fiscal 2003 Results Summary and Fiscal 2004 Targets Self-Medication Operation Group Prescription
Financial Results of Astellas for Fiscal Year 2017
Contact: Corporate Communications, Astellas Pharma Inc. TEL +81-3-3244-3201 April 26, 2018 Financial Results of Astellas for Fiscal Year 2017 Japan, April 26, 2018 Astellas Pharma Inc. (TSE: 4503, President
Financial Results for the First Half of Fiscal Year Ending March 31, 2018 (FY2017)
Financial Results for the First Half of Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer, Investor Relations, Corporate Communication Dept. Kazuaki Kitabatake November
Kyowa Hakko Kirin Co., Ltd.
Kyowa Hakko Kirin Co., Ltd. Consolidated Financial Summary (IFRS) Fiscal 2018 Third Quarter (January 1, 2018 September 30, 2018) This document is an English translation of parts of the Japanese-language
Q Results. 25 April 2018
Q1 2018 Results 25 April 2018 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group s current expectations
Investor Meeting on Q1 FY2017 Results
Investor Meeting on FY2017 Results Kazuo Koshiji Senior Corporate Officer Chief Financial Officer (CFO) Head of Finance Division August 1, 2017 Copyright 2017 Santen Pharmaceutical Co., Ltd. All rights
May 11, 2017 KYORIN Holdings, Inc. P.13 P.2 P.3 P.15. reference 7. Segment information 8. P&L Summary 9. BS Summary
Consolidated Financial Results for the Fiscal Year Ending March 31, 2017 1. Outline of Consolidated Financial Results 2. Highlights of Business Performance 3. Consolidated Financial Results 4. Main Product
Driven by Core Competencies Santen is emphasizing strong fundamentals to enhance its market position and expand its product portfolio.
ANNUAL REPORT 2003 Year ended March 31, 2003 Driven by Core Competencies Santen is emphasizing strong fundamentals to enhance its market position and expand its product portfolio. Profile Santen Pharmaceutical
Financial Results for the 2nd Quarter of the Fiscal Year ending January 31, 2019
(TSE Stock Code:4592) Financial Results for the 2nd Quarter of the Fiscal Year ending January 31, 2019 SanBio Company Limited Representative Director and President Keita Mori September 20, 2018 2018 SanBio
LILLY ELI & CO FORM 10-Q. (Quarterly Report) Filed 10/27/17 for the Period Ending 09/30/17
LILLY ELI & CO FORM 10-Q (Quarterly Report) Filed 10/27/17 for the Period Ending 09/30/17 Address LILLY CORPORATE CTR DROP CODE 1112 INDIANAPOLIS, IN, 46285 Telephone 3172762000 CIK 0000059478 Symbol LLY
Earnings of 3Q FY2011/3
Earnings of 3Q FY2011/3 (April 1 December 31, 2010) January 28, 2011 FORWARDLOOKING STATEMENTS Forwardlooking statements such as those relating to earnings forecasts and other projections contained in
Puma Biotechnology Reports Third Quarter 2018 Financial Results
News Release Puma Biotechnology Reports Third Quarter 2018 Financial Results LOS ANGELES, Calif., Nov. 01, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial
[This page is intentionally left blank] 2
![[This page is intentionally left blank] 2](/thumbs/88/115311617.jpg "[This page is intentionally left blank] 2")
Tokyo, October 31, 2018 2018 Third Quarter Results Highlights Adjusted operating profit at constant FX increased 9.2% year on year or 5.1% on a reported basis. Strong performance in the international tobacco
Financial Results Supplemental Material. FY2017 Fourth Quarter
Financial Results Supplemental Material FY2017 Fourth Quarter [This slide intentionally left blank] Data Sheets Terms Adjusted Operating Profit Consolidated Adjusted Operating Profit at Constant FX Total
Financial Results for the Fiscal Year Ended March 31, 2017 (FY2016) and Guidance for the Fiscal Year Ending March 31, 2018 (FY2017)
Financial Results for the Fiscal Year Ended March 31, 2017 (FY2016) and Guidance for the Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer, Investor Relations, Corporate
Innovative Prescription Drug Management from Great-West Life
Issue 1 June 2011 Innovative Prescription Drug Management from Great-West Life Is your plan keeping pace? Prescription drug benefits play a significant role in the overall health and well-being of your
Immutep Limited EQUITY RESEARCH PRICE TARGET CHANGE. Buy. IMMP - NASDAQ February 15, Biotechnology
EQUITY RESEARCH PRICE TARGET CHANGE Jason Kolbert (212) 895-3516 jkolbert@maximgrp.com Biotechnology IMMP - NASDAQ February 15, 2018 Closing Price 02/14/2018 $1.77 Rating: 12-Month Target Price: (prior
Third Quarter Results (ended December 31, 2015) Brother Industries, Ltd.
Fiscal Year 2015 (ending March 31, 2016) Third Quarter Results (ended December 31, 2015) Brother Industries, Ltd. February 2, 2016 Information on this report, other than historical facts, refers to future
Innovative Prescription Drug Management from Great-West Life
Issue 1 Innovative Prescription Drug Management from Great-West Life Is your plan keeping pace? Prescription drug benefits play a significant role in the overall health and well-being of your employees,
Investor Meeting on FY2016 First Quarter Results and FY2016 Forecasts
Investor Meeting on FY2016 First Quarter Results and FY2016 Forecasts Kazuo Koshiji Senior Corporate Officer Chief Financial Officer (CFO) Head of Finance Division August 2, 2016 Copyright 2016 Santen
Financial Results of Astellas for the First Nine Months of FY2017
Contact: Corporate Communications, Astellas Pharma Inc. TEL +81-3-3244-3201 January 31, 2018 Financial Results of Astellas for the First Nine Months of FY2017 Japan, January 31, 2018 Astellas Pharma Inc.
Financial Results for the First Quarter of Fiscal Year Ending March 31, 2019 (FY2018)
Financial Results for the First Quarter of Fiscal Year Ending March 31, 2019 (FY2018) Terumo Corporation Managing Executive Officer, Kazuaki Kitabatake August 8, 2018 In Line with the Guidance on the Whole
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results
Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results -- Multiple Clinical Data Readouts Expected Throughout 2017 -- NEW YORK, March 22, 2017 Kadmon Holdings, Inc.
MOLOGEN AG: Interim Financial Statements as of March 31, 2010
MOLOGEN AG: Interim Financial Statements as of March 31, 2010 Content Foreword... Page 3 Interim management report for the period from January 1 to March 31, 2010... Page 5 Statement of financial position
Financial Results for the Fiscal Year Ended March 31, 2016
Financial Results for the Fiscal Year Ended March 31, 2016 April 28, 2016 NEC Corporation (http://www.nec.com/en/global/ir) 1 NEC Corporation 2016 Index Ⅰ. Financial Results for Ⅱ. Financial Forecasts
First Quarter (April 1 June 30, ) Flash Report (unaudited) Three months ended June 30, Consolidated Financial Forecast for the Six Months Ending Septe
First Quarter (April 1 June 30, ) Flash Report (unaudited) Three months ended June 30, ONO PHARMACEUTICAL CO., LTD. August 2, Ono Pharmaceutical Co., Ltd. ("The Company") has announced its consolidated
Financial Results for the Third Quarter of Fiscal Year 2017(Consolidated) February 5, 2018 Name of Listed Company: SHIONOGI & CO., LTD.
Financial Results for the Third Quarter of Fiscal Year 2017(Consolidated) February 5, 2018 Name of Listed Company: SHIONOGI & CO., LTD. Listed Exchanges: Section I of Tokyo Code: 4507 URL: http://www.shionogi.co.jp
Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2009
August 6, 2009 Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 BETHESDA, Md.-- Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today reported its consolidated financial results
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 (IFRS)
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2019 (IFRS) August 1, 2018 Company name : Ono Pharmaceutical Co., Ltd. Stock exchange listing : Tokyo Stock Exchange
4Q & FULL-YEAR 2018 EARNINGS CALL. February 2019
4Q & FULL-YEAR 2018 EARNINGS CALL February 2019 We are an innovative, global healthcare leader, committed to improving health and well-being around the world. Forward-Looking Statement This presentation
Investors Meeting Presentation for Q2 FY2018 (April 1 to September 30, 2018)
Investors Meeting Presentation for Q2 FY2018 (April 1 to September 30, 2018) October 31, 2018 Sumitomo Dainippon Pharma Co., Ltd. Disclaimer Regarding Forward-looking Statements This material contains
GS Yuasa Corporation Consolidated Earnings Report for the Nine Months ended December 31, 2018 (Japanese GAAP)
GS Yuasa Corporation Consolidated Earnings Report for the (Japanese GAAP) February 12, 2019 Stock listing: Tokyo Stock Exchange Securities code: 6674 URL: http://www.gs-yuasa.com/en/ Representative: Osamu
Ended March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer
Financial ca Results for the Fiscal Year Ended March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer Kazuaki Kitabatake May 9, 2018 Achieved Highest Ever Revenue and All s FY16YTD FY17YTD
Solid start toward mid-to-high single digit growth in adjusted operating profit at constant FX
FOR IMMEDIATE RELEASE Tokyo, April 30, JT s Consolidated Financial Results for FY First Quarter Solid start toward mid-to-high single digit growth in adjusted operating profit at constant FX Results for
Investor Meeting on Q2 FY2017 Results
Investor Meeting on FY2017 Results Akira Kurokawa President & CEO November 2, 2017 Copyright 2017 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 Santen s Values By focusing on ophthalmology, Santen
FY2017 Financial Results Briefing Material
FY2017 Financial Results Briefing Material February 19, 2018 The Yokohama Rubber Co., Ltd. 1 As introduced, I am Gota Matsuo, head of the Corporate Finance & Accounting Department. I would like to provide
P o r t o l A 2013 Ann Port 2013 Inno ol vative SCIenCe. PaA tient Fo CuSed. u A l r E P o r t
PortolA nl 2013 InnovatIve SCIenCe. lc PatIent FoCuSed. tnov patients Our VariOus academic collaborators VariOus portola employees our company We are POrTOla PHarMaCeUTICalS. Our mission is to build a
FLEXI HEALTH PLAN INDIVIDUAL AND FAMILY HEALTH INSURANCE PLAN APPLICATION FORM
FLEXI HEALTH PLAN INDIVIDUAL AND FAMILY HEALTH INSURANCE PLAN APPLICATION FORM Please use BLOCK letters to complete this form. Proposal form once accepted, becomes part of the policy document. Member Information
Spring Investor Conference 2003
Spring Investor Conference 2003 Rolf Classon, Bayer HealthCare Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.
Zealand Pharma A/S Interim report for the first nine months of 2013 (un-audited)
Company Announcement No. 25/2013 A/S Interim report for the first nine months of 2013 (un-audited) Net result of DKK -139 (EUR -19) million for the first nine months of 2013 Cash and securities of DKK
MEDICAL ASSISTANCE HANDBOOK
PA PROMISe Provider Handbook, NCPDP 5.1/Pharmacy Billing. Table of Contents (Page 2) Section 7 PRIOR AUTHORIZATION 7.5 Benefit Limit Exception for a Drug Prescription 7.5.1 Criteria for a Benefit Limit
Consolidated Financial Results for Fiscal 2005 (Year Ended March 31, 2006)
Consolidated Financial Results for (Year Ended March 31, 2006) FASF May 12, 2006 Listed company name: DAIICHI SANKYO COMPANY, LIMITED Stock code number: 4568 Listed exchanges: Tokyo, Osaka, and Nagoya
Consolidated Financial Results of 2 nd Quarter for the Year Ending March 31, 2019
Consolidated Financial Results of 2 nd Quarter for the Year Ending March 31, 219 November 8, 218 Takashi Shimomura Corporate Officer Division General Manager, Finance Division 1/16 218 Sanden Holdings
Cowen and Company Global Healthcare Conference
March 18, 2009 Cowen and Company Global Healthcare Conference Jim Daly Senior Vice President, North America Commercial Operations Safe Harbor Statement This presentation contains forward-looking statements
Trend Micro FY Q / Annual Results. Mahendra Negi, CFO, Representative director February 4, 2003
Trend Micro FY2002. 4Q / Annual Results Mahendra Negi, CFO, Representative director February 4, 2003 1 Forward Looking Statements Certain statements that we make in this presentation are forward-looking
Date of Birth: Telephone #: Best time to call: City: State: Zip: PLEASE MAKE THE FOLLOWING ADDITION TO MY POLICY:
REQUEST FOR ADDITION/APPLICATION FOR REINSTATEMENT American Family Life Assurance Company of Columbus (AFLAC), Worldwide Headquarters: Columbus, GA 31999 For information, call toll-free 1-800-99-AFLAC
New products drive growth
Half-Year Review 2001 Chairman s and Chief Executive Officer s statement Financial highlights business performance New products drive growth Sales Trading profit Earnings Q2 Dividend 9,879m 2,911m 2,199m
FY 2018 Third-Quarter Financial Results Briefing Material
FY Third-Quarter Financial Results Briefing Material November 9, The Yokohama Rubber Co., Ltd. Voluntary Adoption of IFRS Yokohama Rubber Group voluntarily adopted the International Financial Reporting
Employee Benefits Open Enrollment 2016
Employee Benefits Open Enrollment 2016 Plan Year Costs Includes Medical, RX, Vision & Dental 2016/2017estimated Financial Pressures AU Budget Challenges Trend on healthcare costs Aging population Cost
XOMA Reports First Quarter 2006 Results *********************************************************************
News Release Paul Goodson Investor Relations Tel: (510) 204-7270 XOMA Reports First Quarter 2006 Results ********************************************************************* Berkeley, CA May 10, 2006
Highlights of Consolidated Results for Fiscal Year ended March 31, 2016
May 9, 2016 Highlights of Consolidated Results for Fiscal Year ended March 31, 2016 (except for per share amounts) Year ended Year ended March 31, March 31, 2016 2015 Change Y 745,888 Y 707,237 5.5 Operating
Validation of Antibody Mixtures in Cancer
Validation of Antibody Mixtures in Cancer Annual Report 2013 Contents Symphogen in Brief......................................................................................................................
Half-Year Report Finance in brief Key interim results Sales CER growth % Core operating profit margin % of sales Pharmaceuticals +6.7 +5.0 47.2 45.1 Diagnostics +5.8 +5.0 17.1 18.2 Group +6.5 +5.0 39.7
Building Growth Momentum in HealthCare
Building Growth Momentum in HealthCare Marijn Dekkers, CEO September 20, 2011 UBS Life Science Conference Disclaimer This presentation may contain forward-looking statements based on current assumptions
Dr. Reddy s Laboratories
2QFY2017 Result Update Pharmaceutical November 7, 2016 Dr. Reddy s Laboratories Performance Highlights Y/E March (` cr) 2QFY2017 1QFY2017 % chg (qoq) 2QFY2016 % chg (yoy) Net sales 3,586 3,235 10.9 3,989